Pregabalin suppresses calcium-mediated proteolysis and improves stroke outcome

Neurobiology of Disease

Volumn 41, Issue 3, 2011, Pages 624-629

  Yoon, Jeong Seon ^a   Lee, Jong Hwan ^a   Son, Tae Gen ^a   Mughal, Mohamed R ^a   Greig, Nigel H ^a   Mattson, Mark P ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Calcium; Calpain; Cerebral ischemia; Neuronal death; Pregabalin; Presynaptic calcium channels

Indexed keywords

CALCIUM ION; CALPAIN; FODRIN; PREGABALIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; INHIBITION KINETICS; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TREATMENT OUTCOME;

ANIMALS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; MICE, INBRED C57BL; PROTEOLYSIS; STROKE; TREATMENT OUTCOME;

EID: 79151475812     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.11.011     Document Type: Article

References (23)

1. Barone F.C., Feuerstein G.Z., Spera R.P. Calcium channel blockers in cerebral ischaemia. Expert Opin. Investig. Drugs 1997, 6:501-519.
2. Bartus R.T., Dean R.L., Cavanaugh K., Eveleth D., Carriero D.L., Lynch G. Time-related neuronal changes following middle cerebral artery occlusion: implication for therapeutic intervention and the role of calpain. J. Cereb. Blood Flow Metab. 1995, 15:969-979.
3. Bauer C.S., Nieto-Rostro M., Rahman W., Tran-Van-Minh A., Ferron L., Douglas L., et al. The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J. Neurosci. 2009, 29:4076-4088.
4. Bederson J.B., Pitts L.H., Tsuii M., Nishimura M.C., Davis R.L., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
5. Bian F., Offord J., Davis M.D., McCormick J., Taylor C.P. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdale, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res. 2006, 1075:68-80.
6. Choi D.W. Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 1988, 11:465-469.
7. Dutta S., Chiu Y.C., Probert A.W., Wang K.K. Selective release of calpain produced α II-spectrin (α-fodrin) breakdown products by acute neuronal cell death. J. Biol. Chem. 2002, 383:785-791.
8. Glazner G.W., Chan S.L., Lu C., Mattson M.P. Caspase-mediated degradation of AMPA receptor subunits: a mechanism for preventing excitotoxic necrosis and ensuring apoptosis. J. Neurosci. 2000, 20:3641-3649.
9. Hanson J.E., Smith Y. Subcellular distribution of high-voltage-activated calcium channel subtypes in rat globus pallidus neurons. J. Comp. Neurol. 2002, 442:89-98.
10. Hossmann K.A. Pathophysiology and therapy of experimental stroke. Cell. Mol. Neurobiol. 2006, 26:1057-1083.
11. Joshi I., Taylor C.P. Pregabalin action at a model synapse: binding to presynaptic calcium channel alpha2-delta subunit reduces neurotransmission in mice. Eur. J. Pharmacol. 2006, 553:82-88.
12. Lee K.S., Frank S., Vanderklish P., Arai A., Lynch G. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc. Natl Acad. Sci. USA 1991, 88:7233-7237.
13. Lyseng-Williamson K.A., Siddiqui M.A.A. Pregabalin: a review of its use in fibromyalgia. Drugs 2008, 68:2205-2223.
14. Mize R.R., Graham S.K., Cork R.J. Expression of the L-type calcium channel in the developing mouse visual system by use of immunocytochemistry. Brain Res. Dev. Brain Res. 2002, 136:185-195.
15. Muir K.W. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr. Opin. Pharmacol. 2006, 6:53-60.
16. Pike B.R., Flint J., Dave J.R., Lu X.C., Wang K.K., Tortella F.C., Hayes R.L. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 2004, 24:98-106.
17. Shimamura N., Matchett G., Tsubokawa T., Ohkuma H., Zhang J. Comparison of silicon-coated nylon suture to plain nylon suture in the rat middle cerebral artery occlusion model. J. Neurosci. Meth. 2006, 156:161-165.
18. Shneker B.F., McAuley J.W. Pregabalin: a new neuromodulator with broad therapeutic indications. Ann. Pharmacother. 2005, 39:2029-2037.
19. Swanson R.A., Sharp F.R. Infarct measurement methodology. J. Cereb. Blood Flow Metab. 1994, 14:697-698.
20. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007, 73:137-150.
21. Tomassoni D., Lanari A., Silvestrelli G., Traini E., Amenta F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin. Exp. Hypertens. 2008, 30:744-766.
22. Tuttolomondo A., Sciacca R.D., Raimondo D.D., Arnao V., Renda C., Pinto A., et al. Neuron protection as therapeutic target in acute ischemic stroke. Curr. Top. Med. Chem. 2009, 9:1317-1334.
23. Vermeij T.C.A., Edelbroek P.M. Stimultaneous high-performance liquid chromatographic analysis of pregabalin, gabapentin and vigabatrin in human serum by precolumn derivatization with o-phtaldialdehyde and fluorescence detection. J. Chromatogr. B 2004, 810:297-303.